

# **Proteome Sciences plc**

## **PRESS RELEASE**

**For immediate release**

**4<sup>th</sup> July 2005**

### **AGM STATEMENT**

At the Annual General Meeting of Proteome Sciences plc (“the Company”) being held at 10.30am today, the following statement will be read out by Steve Harris, Chairman:

“As stated in the Annual Report for 2004, the Board believes that the Company’s general prospects remain most promising. Progress continues to be made in concluding the licence agreement for the Company’s Mass Tandem Tags® technology, and a strong expansion of commercial activity from the three main divisions of the business is still expected.”

**ENDS**

**For further information please contact:**

#### **Proteome Sciences plc**

www.proteomics.com

Christopher Pearce, Chief Executive

Tel: +44 (0)1932 865065

Email: [christopher.pearce@proteomics.com](mailto:christopher.pearce@proteomics.com)

#### **Public Relations for Proteome Sciences**

##### **IKON Associates**

Adrian Shaw

Tel: +44 (0)1483 535102

Mobile: +44 (0)797 9900733

Email: [adrian@ikonassociates.com](mailto:adrian@ikonassociates.com)

#### **Notes to Editors:**

**Proteome Sciences plc** applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has to date developed sensitive blood assays for stroke, vCJD, BSE, solid organ transplant rejection and Alzheimer’s disease. The main focus of its research currently addresses neurological, neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoShop® (Proteome Sciences High Output Proteomics), a tool box that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification of potential biomarkers and drug targets. These include specialisation in membrane proteins and protein phosphorylation.

The Company has developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer®, PST® qPST® and TMT®.

Commercialisation is actively pursued across the portfolio of the Company's programmes and technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoShop®.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has laboratories at King's College Hospital, London and in Frankfurt. It employs 40 full time scientists, in addition to its corporate and business development staff. The Company is listed on the Alternative Investment Market.